Showing: 1 - 3 of 3 RESULTS

Pear Therapeutics to Participate in Upcoming Investor Conferences

Pear Therapeutics, Inc. today announced management’s participation in three virtual investor conferences in October 2020:

  • Cowen 9th Annual MedTools Conference – Answers Unlocked. Corey McCann, M.D., Ph.D., President and CEO, will participate in a panel discussion, Digital Therapeutics, at this virtual conference on Thursday, October 15, 2020 at 8:30 a.m. ET.

  • 7th Solebury Trout Private Company Showcase Co-Hosted by BMO and Davis Polk. Corey McCann will present at this virtual conference on Thursday, October 15, 2020 at 11:40 a.m. ET.

  • HLTH VRTL 2020 Conference – Evercore ISI Panel Series Digging into Digital Therapeutics: A New Dimension in Treatment. Corey McCann will participate in a panel discussion, CEOs on DTx, at this virtual conference on Friday, October 16, 2020 at 11:00 a.m. ET.

Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.

About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™, for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005153/en/

Contacts

Media and Investors:
Meara Murphy, Director, Corporate Communications
[email protected]

 

Source Article

Trump campaign says president plans to participate in next debate in person despite uncertainty

President TrumpDonald John TrumpState Department revokes visa of Giuliani-linked Ukrainian ally: report White House Gift Shop selling ‘Trump Defeats COVID’ commemorative coin Biden says he should not have called Trump a clown in first debate MORE plans to participate in next week’s debate in person, his campaign said Tuesday, despite uncertainty around how he will recover from COVID-19.

“The President intends to participate in the debate in person,” the campaign’s communications director, Tim Murtaugh, said in a statement to The Hill.

But it’s unclear if the president will be healthy enough to attend the debate, or whether he would be exposing other attendees to a contagious virus that has killed roughly 210,000 people in the U.S. to date.

Trump himself signaled earlier in the day that he would take part in the debate, though he did not specify whether he might do so virtually.

“I am looking forward to the debate on the evening of Thursday, October 15th in Miami. It will be great!” Trump tweeted.

Trump first revealed that he tested positive for COVID-19 early Friday morning, and he has had symptoms since at least then. But the White House has refused to say when Trump last tested negative or fill in the timeline around his diagnosis.

The Centers for Disease Control and Prevention (CDC) guidelines state that adults with mild to moderate COVID-19 can be around others 10 days after symptoms first appeared so long as they have gone 24 hours without a fever and other symptoms are improving.

The debate is scheduled to take place on Oct. 15, which would be 13 days from when Trump first revealed his diagnosis.

The president was on oxygen as recently as last Saturday, but he was discharged from Walter Reed National Military Medical Center on Monday evening after doctors said his vitals had improved and he passed clinical evaluations. But they acknowledged he is not out of the woods yet, citing next Monday as the point at which they will breathe a sigh of relief.

Democratic presidential nominee Joe BidenJoe BidenState Department revokes visa of Giuliani-linked Ukrainian ally: report Biden says he should not have called Trump a clown in first debate Biden inquired about calling Trump after coronavirus diagnosis MORE has said he would take part in next week’s town hall-style debate if medical experts deem it safe.

“If the scientists say that it’s safe, that the distances are safe, then I think that’s fine,” Biden said Monday. “I’ll do whatever the experts say is appropriate thing to do.”

Source Article

Editas Medicine to Participate in Upcoming Investor Conference

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

October 1, 2020 GMT

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conference:

Chardan Virtual 4th Annual Genetic Medicines Conference
Fireside Chat
Date: Monday, October 5, 2020
Time: 10:30 a.m. ET

The event will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the event.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Investor Contact
Mark Mullikin
(617) 401-9083
[email protected]

Media Contact
Cristi Barnett
(617) 401-0113
[email protected]

Source Article